RE:RE:RE:Endo is our partner.........I agree in that I think a lot of the negative bias and the "no" votes are a result of Telesta attempting to go it alone in the U.S. It wouldn't surprise me any if this isn't an extemely relevant factor in these U.S. voting members extreme negative arguments and associated voting results.
I would add that I don't think Endo is any champion in Telesta's cause of getting MCNA to market here. Far from it. It is my opinion that Endo may perhaps be very much in the background supporting this callous negative bias in order to derail this drug. Why would Endo support Telesta's drug that they have a 5% royalty in? MCNA would thereby end their monopoly of second line treatment of Valastar whitch is 100% profit to Endo? Albeit much to the apparent detriment of bladder cancer victims.
I just wonder what the vote would have been if Telesta was partnered with a large US pharma for the US market? This may have been a huge mistake for Telesta going for too much of the US pie. Maybe just having the huge new block of US investors that occurred with the latest financing was just not enough support to offset not having a US pharma onboard. Maybe none of this was a factor, but worthy of consideration.